Teva
14 products tracked · names used in filings: Teva, Teva GmbH, Teva Pharma GmbH, Teva Pharmaceuticals, Inc.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
FDA approves Weltruza (olanzapine): new formulation or manufacturer
Teva; NDA219007; New formulation or manufacturer; powder · source
FDA approves biosimilar Degevma (denosumab-adet)
Teva Pharmaceuticals, Inc.; BLA761481; Biosimilar; injectable · source
FDA approves biosimilar Ponlimsi (denosumab-adet)
Teva Pharmaceuticals, Inc.; BLA761385; Biosimilar; injectable · source
Austedo (deutetrabenazine) approved in the EU
Marketing authorisation to Teva GmbH; Additional monitoring · source
Ponlimsi (denosumab) approved in the EU
Marketing authorisation to Teva GmbH; Biosimilar, Additional monitoring · source
Degevma (denosumab) approved in the EU
Marketing authorisation to Teva GmbH; Biosimilar, Additional monitoring · source
Austedo (deutetrabenazine): CHMP positive opinion
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Nerventra laquinimod | Refused | |
| 🇪🇺 | Dabigatran etexilate Teva dabigatran etexilate | Application withdrawn | |
| 🇺🇸 | Weltruza olanzapine | Approved | 2026-10-08 |
| 🇺🇸 | Degevma denosumab-adet | Approved | 2026-09-25 |
| 🇺🇸 | Ponlimsi denosumab-adet | Approved | 2026-03-27 |
| 🇪🇺 | Austedo deutetrabenazine | Authorised | 2026-01-08 |
| 🇪🇺 | Degevma denosumab | Authorised | 2025-11-17 |
| 🇪🇺 | Ponlimsi denosumab | Authorised | 2025-11-17 |
| 🇪🇺 | Pomalidomide Teva pomalidomide | Authorised | 2024-11-14 |
| 🇪🇺 | Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma) dabigatran etexilate | Authorised | 2024-02-19 |
| 🇪🇺 | Dimethyl fumarate Teva dimethyl fumarate | Revoked | 2022-12-12 |
| 🇪🇺 | Ajovy fremanezumab | Authorised | 2019-03-28 |
| 🇪🇺 | Biopoin epoetin theta | Authorised | 2009-10-23 |
| 🇪🇺 | Tevagrastim filgrastim | Authorised | 2008-09-15 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.